Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy
- 1 August 2008
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 13 (8), 911-920
- https://doi.org/10.1634/theoncologist.2008-0091
Abstract
Cases of osteonecrosis of the jaw (ONJ) have been reported with an increasing frequency over the past 5 years. ONJ is most often identified in patients with cancer who are receiving intravenous bisphosphonate (IVBP) therapy, but it has also been diagnosed in patients receiving oral bisphosphonates for nonmalignant conditions. To further categorize risk factors associated with ONJ and potential clinical outcomes of this condition, we performed a retrospective study of patients with metastatic bone disease treated with intravenous bisphosphonates who have been evaluated by the Memorial Sloan-Kettering Cancer Center Dental Service between January 1, 1996 and January 31, 2006. We identified 310 patients who met these criteria. Twenty-eight patients were identified as having ONJ at presentation to the Dental Service and an additional 7 patients were subsequently diagnosed with ONJ. Statistically significant factors associated with increased likelihood of ONJ included type of cancer, duration of bisphosphonate therapy, sequential IVBP treatment with pamidronate followed by zoledronic acid, comorbid osteoarthritis or rheumatoid arthritis, and benign hematologic conditions. Our data do not support corticosteroid use or oral health as a predictor of risk for ONJ. Clinical outcomes of patients with ONJ were variable with 11 patients demonstrating improvement or healing with conservative management. Our ONJ experience is presented here.Keywords
This publication has 29 references indexed in Scilit:
- Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2007
- Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jawsDento maxillo facial radiology, 2006
- Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk FactorsJournal of Clinical Oncology, 2005
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Angiogenesis, Vasculogenesis, and Induction of Healing in Chronic WoundsVascular and Endovascular Surgery, 2005
- Bisphosphonate‐associated osteonecrosis of mandibular and maxillary boneCancer, 2005
- Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 casesJournal of Oral Pathology & Medicine, 2005
- Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic AcidJournal of Pharmacology and Experimental Therapeutics, 2002
- Angiogenesis and Bone GrowthTrends in Cardiovascular Medicine, 2000
- The Hallmarks of CancerCell, 2000